Peptide-retargeted adenovirus encoding a tissue inhibitor of metalloproteinase-1 decreases restenosis after intravascular gene transfer.

In this study we have attached cyclic targeting peptides by way of a poly-lysine spacer on the surface of an adenovirus using a transglutaminase enzymatic reaction to enhance transduction efficiency and to modify tissue tropism in vivo. Nuclear targeted lacZ- and TIMP-1-encoding adenoviruses were coupled to a peptide-motif (HWGF) that can bind to matrix metalloproteinase (MMP)-2 and MMP-9. Modified viruses were used to evaluate gene transfer efficiency, biodistribution, and the effect on neointima formation following balloon denudation injury. In vitro, both rabbit aortic smooth muscle cells and human endothelial hybridoma cells demonstrated significantly increased reporter gene expression with HWGF-modified adenoviruses (AdlacZ(HWGF)) compared with control (AdlacZ) or mismatch peptide-modified (AdlacZ(MM)) adenoviruses. However, in human hepatocellular Hep-G2 cells, both AdlacZ(HWGF) and AdlacZ(MM) produced significantly lower transgene expression compared with the respective control viruses. In vivo, local intravascular catheter-mediated gene transfer of a HWGF-targeted TIMP-1-encoding adenovirus (AdTIMP-1(HWGF)) significantly reduced intimal thickening in a rabbit aortic balloon denudation model (P < 0.05) compared with the control adenovirus. X-Gal staining and biodistribution analyses with TaqMan RT-PCR revealed that the cyclic peptides altered vector tropism and, in particular, reduced transduction of the liver. We found that the HWGF peptide modification increased transduction efficiency of the adenovirus-mediated gene transfer in smooth muscle cells and endothelial cells in in vitro and enhanced gene transfer to the arterial wall in vivo; that peptide modification of adenoviruses beneficially modulated tissue tropism in vivo; and that efficient TIMP-1 gene transfer reduced intimal thickening in an established restenosis model in rabbits.

[1]  A. Herrmann,et al.  Targeting of high-capacity adenoviral vectors. , 2001, Human gene therapy.

[2]  Seppo Ylä-Herttuala,et al.  Clinical applications of vascular gene therapy , 2001, Current cardiology reports.

[3]  S. Borzak,et al.  Treatment possibilities for unstable angina , 2000, BMJ : British Medical Journal.

[4]  V. Kosma,et al.  Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  J. Hartikainen,et al.  Intravascular Adenovirus-Mediated VEGF-C Gene Transfer Reduces Neointima Formation in Balloon-Denuded Rabbit Aorta , 2000, Circulation.

[6]  S. Ylä-Herttuala,et al.  Cardiovascular gene therapy , 2000, The Lancet.

[7]  G. Pierce,et al.  Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors. , 2000, Human gene therapy.

[8]  A. Houtsmuller,et al.  Expression of Coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers , 1999, Gene Therapy.

[9]  Timo Sorsa,et al.  Tumor targeting with a selective gelatinase inhibitor , 1999, Nature Biotechnology.

[10]  J. McEwan,et al.  Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. , 1999, Circulation.

[11]  H. Ishibashi-Ueda,et al.  Coronary atherosclerosis and interventions: Pathological sequences and restenosis , 1999, Pathology international.

[12]  R. Crystal,et al.  CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. , 1999, The Journal of clinical investigation.

[13]  F. Szoka,et al.  Efficient adventitial gene delivery to rabbit carotid artery with cationic polymer–plasmid complexes , 1999, Gene Therapy.

[14]  S. George Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis. , 1998, Current opinion in lipidology.

[15]  S. Ylä-Herttuala,et al.  Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. , 1998, Human gene therapy.

[16]  J. Hartikainen,et al.  Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia. , 1998, Human gene therapy.

[17]  G. Angelini,et al.  Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. , 1998, Human gene therapy.

[18]  A. Baker,et al.  Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. , 1998, The Journal of clinical investigation.

[19]  R. Assoian,et al.  The extracellular matrix as a cell cycle control element in atherosclerosis and restenosis. , 1996, The Journal of clinical investigation.

[20]  J. Greene,et al.  Molecular Cloning and Characterization of Human Tissue Inhibitor of Metalloproteinase 4* , 1996, The Journal of Biological Chemistry.

[21]  J. Bittl,et al.  Advances in coronary angioplasty. , 1996, The New England journal of medicine.

[22]  A. Clowes,et al.  Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. , 1996, Circulation research.

[23]  W. Stetler-Stevenson,et al.  Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3 , 1996, Cell.

[24]  N. Fineberg,et al.  Vascular injury, repair, and restenosis after percutaneous transluminal angioplasty in the atherosclerotic rabbit. , 1995, Circulation.

[25]  J. McEwan,et al.  Matrix metalloproteinases and cardiovascular disease. , 1995, Circulation research.

[26]  M. Ferguson,et al.  Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. , 1995, Circulation.

[27]  R. Califf Restenosis: the cost to society. , 1995, American heart journal.

[28]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[29]  K Zatloukal,et al.  Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[30]  F. Breedveld,et al.  Methods for the detection of anti-endothelial antibodies by enzyme-linked immunosorbent assay. , 1991, Journal of immunological methods.

[31]  Z. Werb,et al.  92-kD type IV collagenase mediates invasion of human cytotrophoblasts , 1991, The Journal of cell biology.

[32]  R. Hembry,et al.  Metalloproteinases and tissue damage. , 1991, British journal of rheumatology.

[33]  P W Serruys,et al.  Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. , 1988, Circulation.